PMGC Holdings Inc.(ELAB)Earnings, Financials & Key Ratios
ELAB•NASDAQ
$2.16
$49114 mkt cap·Price updated May 7, 2026
AboutPMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.Show more
- Revenue$2M+44.1%
- EBITDA-$2M+52.4%
- Net Income-$6M-45.2%
- EPS (Diluted)-274.68+86.0%
- Gross Margin72.84%+9.9%
- EBITDA Margin-72.28%+67.0%
- Operating Margin-75.65%+65.5%
- Net Margin-253.14%-0.8%
- ROE-119.12%+31.3%
- ROIC-82.69%+85.8%
- Interest Coverage-2.54+98.7%
ELAB Key Insights
PMGC Holdings Inc. (ELAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 96.7% through buybacks
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ELAB Price & Volume
PMGC Holdings Inc. (ELAB) stock price & volume — 10-year historical chart
Loading chart...
ELAB Growth Metrics
PMGC Holdings Inc. (ELAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years1339.59%
TTM-179.8%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM89.91%
Return on Capital
10 Years-187.48%
5 Years-187.48%
3 Years-127.41%
Last Year-33.67%
ELAB Peer Comparison
PMGC Holdings Inc. (ELAB) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HOFV | 2.35M | 0.35 | -0.04 | -12.12% | -366.24% | -207.29% | 3.45 | |
 GFAI | 10.31M | 0.47 | -0.89 | 0.18% | -32.94% | -69.69% | 0.08 | |
 AEYE | 100.43M | 8.09 | -32.36 | 14.52% | -7.63% | -47.8% | 0.15 | |
 GAME | 17.46M | 0.45 | -0.26 | 132.91% | -46.12% | -321.08% | 1.97 | |
 AGAE | 19.77M | 0.52 | -1.16 | 18.6% | -290.24% | -9.45% | 0.40 | |
 SKLZ | 108.93M | 6.98 | -1.55 | 9.46% | -67.38% | -52.52% | 1.15 | |
 DKNG | 12.5B | 25.22 | -3113.58 | 26.99% | 0.06% | 0.46% | 3.06 | |
 PENN | 2.24B | 16.77 | -2.88 | 5.82% | -12.11% | -34.66% | 4.58 |
Compare ELAB vs Peers
PMGC Holdings Inc. (ELAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ELAB Income Statement
PMGC Holdings Inc. (ELAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 827 | 766.28K | 1.71M | 2.47M | -1.46M |
| Revenue Growth % | - | - | 92557.44% | 123.5% | 44.07% | -179.8% |
| Cost of Goods Sold | 0 | 2.85K | 318.97K | 578.01K | 670.2K | 258.67K |
| COGS % of Revenue | - | 344.01% | 41.63% | 33.75% | 27.16% | - |
| Gross Profit | 0▲ 0% | -2.02K▲ 0% | 447.31K▲ 22266.0% | 1.13M▲ 153.6% | 1.8M▲ 58.4% | -1.72M▲ 0% |
| Gross Margin % | - | -244.01% | 58.37% | 66.25% | 72.84% | - |
| Gross Profit Growth % | - | - | 22265.96% | 153.65% | 58.39% | - |
| Operating Expenses | 222.91K | 783.04K | 2.24M | 4.89M | 3.66M | 2.34M |
| OpEx % of Revenue | - | 94684.89% | 291.75% | 285.82% | 148.48% | - |
| Selling, General & Admin | 102.99K | 633.96K | 1.73M | 4.03M | 855.76K | 2.94M |
| SG&A % of Revenue | - | 76658.04% | 225.69% | 235.2% | 34.68% | - |
| Research & Development | 118.86K | 123.63K | 228.75K | 426.24K | 104.65K | -64.25K |
| R&D % of Revenue | - | 14949.46% | 29.85% | 24.89% | 4.24% | - |
| Other Operating Expenses | 0 | 25.45K | 277.48K | 440.45K | 2.7M | -541.32K |
| Operating Income | -221.84K▲ 0% | -785.06K▼ 253.9% | -1.79M▼ 127.8% | -3.76M▼ 110.3% | -1.87M▲ 50.4% | -4.06M▲ 0% |
| Operating Margin % | - | -94928.66% | -233.37% | -219.55% | -75.65% | - |
| Operating Income Growth % | - | -253.88% | -127.79% | -110.26% | 50.36% | - |
| EBITDA | 0 | -782.3K | -1.78M | -3.75M | -1.78M | -4M |
| EBITDA Margin % | - | -94595.28% | -232.52% | -218.87% | -72.28% | - |
| EBITDA Growth % | - | - | -127.76% | -110.38% | 52.42% | 3.55% |
| D&A (Non-Cash Add-back) | 221.84K | 2.76K | 6.51K | 11.65K | 83.1K | 53.98K |
| EBIT | -221.84K | -784.74K | -1.8M | -4.28M | -3.28M | -4.24M |
| Net Interest Income | 0 | 0 | 5.07K | -13.96K | -722.31K | -137.44K |
| Interest Income | 0 | 0 | 7.7K | 5.56K | 12.89K | 102.44K |
| Interest Expense | 0 | 0 | 2.63K | 19.52K | 735.2K | 239.88K |
| Other Income/Expense | -1.07K | 321 | -11.98K | -541.44K | -2.15M | -424.1K |
| Pretax Income | -222.91K▲ 0% | -784.74K▼ 252.0% | -1.8M▼ 129.4% | -4.3M▼ 138.9% | -4.02M▲ 6.6% | -4.48M▲ 0% |
| Pretax Margin % | - | -94889.84% | -234.94% | -251.17% | -162.8% | 306.65% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -222.91K▲ 0% | -784.74K▼ 252.0% | -1.8M▼ 129.4% | -4.3M▼ 138.9% | -6.25M▼ 45.2% | -6.66M▲ 0% |
| Net Margin % | - | -94889.84% | -234.94% | -251.17% | -253.14% | - |
| Net Income Growth % | - | -252.04% | -129.41% | -138.94% | -45.2% | -21.78% |
| Net Income (Continuing) | -222.91K | -784.74K | -1.8M | -4.3M | -4.02M | -4.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -2.23M | 50.87K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.08▲ 0% | -0.29▼ 251.3% | -0.67▼ 129.2% | -1961.37▼ 294842.1% | -274.68▲ 86.0% | -12.60▲ 0% |
| EPS Growth % | - | -251.27% | -129.19% | -294842.11% | 86% | 89.91% |
| EPS (Basic) | -0.08 | -0.29 | -0.67 | -1961.37 | -274.68 | - |
| Diluted Shares Outstanding | 2.7M | 2.7M | 2.72M | 682.91K | 22.74K | 528.47K |
| Basic Shares Outstanding | 2.7M | 2.7M | 2.72M | 2.19K | 22.74K | 528.47K |
| Dividend Payout Ratio | - | - | - | - | - | - |
ELAB Balance Sheet
PMGC Holdings Inc. (ELAB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 17.02K | 636.52K | 1.55M | 4.92M | 6.05M | 9.77M |
| Cash & Short-Term Investments | 13.35K | 411.86K | 1.15M | 3.33M | 3.98M | 7.7M |
| Cash Only | 13.35K | 411.86K | 1.15M | 3.33M | 3.98M | 7.7M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 1.71K | 12.85K | 36.16K | 5.28K | 369.43K |
| Days Sales Outstanding | - | 754.72 | 6.12 | 7.71 | 0.78 | -39.4 |
| Inventory | 0 | 160.82K | 230.15K | 495.67K | 1.04K | 128.47K |
| Days Inventory Outstanding | - | 20.63K | 263.36 | 313 | 0.57 | 45.32 |
| Other Current Assets | 3.67K | 0 | 0 | 0 | 1.19M | 1.57M |
| Total Non-Current Assets | 0 | 29.73K | 340.86K | 270.47K | 2.94M | 5.17M |
| Property, Plant & Equipment | 0 | 29.73K | 330.09K | 259.7K | 1.09K | 1.66M |
| Fixed Asset Turnover | - | 0.03x | 2.32x | 6.59x | 2269.82x | -3.53x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 959.53K |
| Intangible Assets | 0 | 0 | 0 | 0 | 2.8M | 2.55M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 139.08K | 139.08K |
| Other Non-Current Assets | 0 | 0 | 10.77K | 10.77K | 0 | 0 |
| Total Assets | 17.02K▲ 0% | 666.25K▲ 3814.1% | 1.89M▲ 184.0% | 5.19M▲ 174.3% | 8.99M▲ 73.3% | 14.94M▲ 0% |
| Asset Turnover | - | 0.00x | 0.40x | 0.33x | 0.27x | -0.14x |
| Asset Growth % | - | 3814.05% | 184% | 174.28% | 73.28% | 301.45% |
| Total Current Liabilities | 40.61K | 215.62K | 588.27K | 1.3M | 1.8M | 5.46M |
| Accounts Payable | 154 | 98.17K | 210.84K | 596.15K | 481K | 0 |
| Days Payables Outstanding | - | 12.6K | 241.27 | 376.45 | 261.96 | 401.1 |
| Short-Term Debt | 24K | 0 | 0 | 0 | 0 | 3.42M |
| Deferred Revenue (Current) | 0 | 0 | 10.17K | 36.69K | 0 | 0 |
| Other Current Liabilities | 16.46K | 0 | 68.45K | 369.16K | 548.92K | 2.04M |
| Current Ratio | 0.42x | 2.95x | 2.64x | 3.79x | 3.36x | 3.36x |
| Quick Ratio | 0.42x | 2.21x | 2.25x | 3.41x | 3.36x | 3.36x |
| Cash Conversion Cycle | - | 8.79K | 28.21 | -55.74 | -260.61 | -395.18 |
| Total Non-Current Liabilities | 0 | 0 | 172.6K | 65.49K | 534.47K | 985.67K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 985.67K |
| Capital Lease Obligations | 0 | 0 | 172.6K | 65.49K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 534.47K | 534.47K |
| Total Liabilities | 40.61K | 215.62K | 760.87K | 1.36M | 2.33M | 6.45M |
| Total Debt | 24K | 0 | 283.22K | 210.49K | 0 | 4.41M |
| Net Debt | 10.65K | -411.86K | -871.68K | -3.12M | -3.98M | -3.29M |
| Debt / Equity | - | - | 0.25x | 0.06x | - | 0.52x |
| Debt / EBITDA | - | - | - | - | - | -1.10x |
| Net Debt / EBITDA | - | - | - | - | - | 0.82x |
| Interest Coverage | - | - | -680.22x | -192.58x | -2.54x | -17.68x |
| Total Equity | -23.59K▲ 0% | 450.63K▲ 2010.3% | 1.13M▲ 151.1% | 3.83M▲ 238.3% | 6.66M▲ 74.0% | 8.49M▲ 0% |
| Equity Growth % | - | 2010.33% | 151.05% | 238.29% | 74.01% | 543% |
| Book Value per Share | -0.01 | 0.17 | 0.42 | 5.60 | 292.88 | 16.07 |
| Total Shareholders' Equity | -23.59K | 450.63K | 1.13M | 3.83M | 6.66M | 8.49M |
| Common Stock | 848 | 952 | 957 | 1.73K | 44 | 74 |
| Retained Earnings | -137.37K | -922.11K | -2.72M | -7.02M | -13.27M | -18.03M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.22K | 202 | 111 | 202 | -337 | -753 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ELAB Cash Flow Statement
PMGC Holdings Inc. (ELAB) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -217.16K | -660.93K | -1.59M | -4.56M | -5.49M | -5.49M |
| Operating CF Margin % | - | -79919.47% | -206.96% | -266.08% | -222.39% | - |
| Operating CF Growth % | - | -204.35% | -139.94% | -187.34% | -20.41% | -304.62% |
| Net Income | -222.91K | -784.74K | -1.8M | -4.3M | -6.25M | -6.66M |
| Depreciation & Amortization | 0 | 2.76K | 6.51K | 11.65K | 12.95K | 40.14K |
| Stock-Based Compensation | 0 | 142.35K | 171.87K | 487.74K | 97.17K | -3.35K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.04K | 600 | 23.58K | 68.51K | 396.97K | 557.88K |
| Working Capital Changes | 6.79K | -21.91K | 12.43K | -823.19K | 251.67K | -57.52K |
| Change in Receivables | -605 | -1.35K | -11.55K | -23.22K | -12.97K | -103.05K |
| Change in Inventory | 0 | -160.82K | -69.33K | -265.52K | -403.3K | 211.96K |
| Change in Payables | 0 | 192.09K | 65.19K | 466.89K | 207.5K | 89.92K |
| Cash from Investing | 0 | -32.48K | -32.03K | -11.19K | -610.56K | -2.66M |
| Capital Expenditures | 0 | -32.48K | -35.53K | -11.19K | -9.16K | -395.59K |
| CapEx % of Revenue | - | 3927.69% | 4.64% | 0.65% | 0.37% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 3.5K | 0 | -462.32K | -1.94M |
| Cash from Financing | 238.28K | 1.09M | 2.36M | 6.74M | 6.76M | 10.12M |
| Debt Issued (Net) | 0 | 0 | 183.97K | 0 | -235.56K | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -179 |
| Other Financing | 238.28K | 0 | 25K | -724.7K | 0 | 1.41M |
| Net Change in Cash | 19.61K▲ 0% | 398.51K▲ 1931.9% | 743.04K▲ 86.5% | 2.17M▲ 192.3% | 657.6K▼ 69.7% | 1.27M▲ 0% |
| Free Cash Flow | -217.16K▲ 0% | -693.42K▼ 219.3% | -1.62M▼ 133.8% | -4.57M▼ 181.7% | -5.49M▼ 20.1% | -6.59M▲ 0% |
| FCF Margin % | - | -83847.16% | -211.59% | -266.73% | -222.39% | - |
| FCF Growth % | - | -219.31% | -133.83% | -181.73% | -20.12% | -9.84% |
| FCF per Share | -0.08 | -0.26 | -0.60 | -6.69 | -241.31 | -241.31 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.84x | 0.88x | 1.06x | 0.88x | 0.99x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 46.57K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
ELAB Key Ratios
PMGC Holdings Inc. (ELAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -367.53% | -227.6% | -173.5% | -119.12% | -78.44% |
| Return on Invested Capital (ROIC) | -4559% | -898.95% | -581.25% | -82.69% | -82.69% |
| Gross Margin | -244.01% | 58.37% | 66.25% | 72.84% | 117.7% |
| Net Margin | -94889.84% | -234.94% | -251.17% | -253.14% | 455.67% |
| Debt / Equity | - | 0.25x | 0.06x | - | 0.52x |
| Interest Coverage | - | -680.22x | -192.58x | -2.54x | -17.68x |
| FCF Conversion | 0.84x | 0.88x | 1.06x | 0.88x | 0.99x |
| Revenue Growth | - | 92557.44% | 123.5% | 44.07% | -179.8% |
ELAB Frequently Asked Questions
PMGC Holdings Inc. (ELAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PMGC Holdings Inc. (ELAB) reported $-1.5M in revenue for fiscal year 2024.
PMGC Holdings Inc. (ELAB) grew revenue by 44.1% over the past year. This is strong growth.
PMGC Holdings Inc. (ELAB) reported a net loss of $6.7M for fiscal year 2024.
Dividend & Returns
PMGC Holdings Inc. (ELAB) has a return on equity (ROE) of -119.1%. Negative ROE indicates the company is unprofitable.
PMGC Holdings Inc. (ELAB) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More ELAB
PMGC Holdings Inc. (ELAB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates